An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.

ABSTRACT:

Importance

Reliable prognostic markers for immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) remain limited.

Objective

To examine the impact of splenic volume change after ICI initiation on progression-free survival (PFS) and overall survival (OS) in patients with mRCC.

Design

A retrospective cohort study reviewing data from 2015 to 2023.

Setting

The Emory Kidney Cancer database (single-center academic instution).

Participants

Patients with mRCC who underwent first-line ICI treatment and had available abdominal imaging 30 days before and 60-120 days after ICI initiation. A total of 109 patients met inclusion criteria.

Exposure

Splenic volume change calculated as a percentage difference between baseline and follow

SUBMITTER: Palmateer G 

PROVIDER: S-EPMC12828282 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature